BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 28, 2025
Home » Authors » Anette Breindl

Articles by Anette Breindl

T cells ChAT with blood vessels via neurotransmitter

Feb. 14, 2019
By Anette Breindl

Bench Press: BioWorld looks at translational medicine

Feb. 11, 2019
By Anette Breindl
Scientists at the University of Salamanca have demonstrated that free radicals or reactive oxygen species (ROS) produced by astrocytes had a beneficial effect on brain metabolism. 
Read More

T cells ChAT with blood vessels via neurotransmitter

Feb. 11, 2019
By Anette Breindl
Researchers have shown that T cells produced the neurotransmitter acetylcholine to affect blood vessel dilation, which helped them control chronic infections. The work was published in the Feb. 8, 2019, issue of Science.
Read More

Reawakening developmental programs may regenerate joints, and one day, limbs

Feb. 8, 2019
By Anette Breindl

Reawakening developmental programs may regenerate joints, and one day, limbs

Feb. 7, 2019
By Anette Breindl
In results that are simple in one sense and profound in another, researchers at Texas A&M University have demonstrated that application of growth factor bone morphogenetic protein 9 (BMP9) could regenerate a joint in mice after an amputation.
Read More

In sexual and reproductive health, necessity is the mother of inventive development

Feb. 4, 2019
By Anette Breindl

In sexual and reproductive health, necessity is the mother of inventive development

Feb. 1, 2019
By Anette Breindl
The easiest explanation for the funding woes of women's health is that women are women and venture capitalists are primarily men. But the aphorism that "there is always a well-known solution to every human problem – neat, plausible and wrong," sometimes ascribed to Mark Twain and sometimes to H.L Mencken, applies.
Read More

In sexual and reproductive health, necessity is the mother of inventive development

Jan. 31, 2019
By Anette Breindl
From a medical perspective, women's sexual and reproductive health is a conundrum. Health care for women of reproductive age includes the possibility of affecting fertility; meanwhile, treating pregnant women means treating two people, whose physiologies differ and whose best interests can be at odds with each other.
Read More

Multitasking neuroprotective drug is surprise BACE-1 inhibitor

Jan. 28, 2019
By Anette Breindl

Focusing on key bonds is novel way to create novel synthesis routes for patent protection

Jan. 28, 2019
By Anette Breindl
Patent protection for drugs hinges on protecting the molecules themselves in composition-of-matter patents. But its structure is only one aspect of a drug that can be protected by patents. Another possibility is to patent the chemical pathway to that structure via composition patents. Pathways, plural, actually – pretty much any compound can be synthesized via multiple routes. The patents around Merck & Co. Inc.'s Januvia (sitagliptin), for example, include more than 400 intermediates, and more than 450 unique reactions.
Read More
Previous 1 2 … 108 109 110 111 112 113 114 115 116 … 392 393 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing